An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen

De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration. Read the full story

Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel Read the full story

Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100 Read the full story

Mesoblast has entered into an Agreement with Celgene Read the full story

MorphoSys has regained rights to MOR202 from Celgene Read the full story

Zymeworks announced a collaboration and licensing agreement with Celgene for the research, development, and commercialization of bi-specific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric platform Read the full story

Amgen and LabCentral biopharma partners: announced an agreement in which Amgen has become a LabCentral platinum sponsor. Read the full story

GeNeuro has entered into a strategic partnership with Servier to develop and market GNbAC1 in Multiple Sclerosis Read the full story

Modern Biosciences has entered into an R&D alliance and global option and licence agreement with Janssen Biotech in relation to MBS’ novel bone-protective compounds for the treatment of rheumatoid arthritis Read the full story

Transposagen Biopharmaceuticals have entered into a research collaboration and worldwide license agreement with Janssen Biotech to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T) Read the full story